<DOC>
	<DOCNO>NCT00588094</DOCNO>
	<brief_summary>The purpose research study treatment program patient aggressive lymphoma come back initial first therapy ( call relapse ) respond first therapy ( call refractory ) . Since 1993 , use combination chemotherapy know ICE ( Ifosfamide , Carboplatin , Etoposide ) type lymphoma . In many patient , treatment help disease shrink give high-dose therapy autologous stem cell transplant ( ASCT ) . Only patient respond type treatment chance disease go away ( remission ) ASCT . In 1999 , study treatment add another medicine type lymphoma , Rituximab ( Rituxan ) , ICE treatment ( RICE ) . More patient lymphoma shrinkage treatment ( chemosensitive disease ) ICE alone . These patient receive high dose therapy autologous stem cell transplant improve chance remission . ICE chemotherapy standard chemotherapy use Memorial Sloan-Kettering Cancer Center . However , different study high dos . We test high dos RICE treatment patient study . In current study Hodgkin 's lymphoma , give high dos ICE ( call augment ICE ) patient also high risk . We hope show study use Rituximab augment ICE improve ability achieve remission ( , disease go away ) .</brief_summary>
	<brief_title>Dose Augmented Rituximab ICE Pts With Primary Refractory Poor Risk Relapsed Aggressive B-Cell NHL</brief_title>
	<detailed_description>The purpose study determine dose escalation rituximab-ICE ( RICEesc ) program improve overall response rate patient primary refractory poor risk relapse aggressive B cell lymphoma . R-ICEesc administer 2 cycle peripheral blood progenitor cell ( PBPCs ) collect cycle 2 . A two-stage design employ , study terminate first cohort patient appear overall response rate &lt; 50 % &gt; 25 % patient fail mobilize least 2 x 106 CD34+ cells/kg .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histologic diagnosis one follow B cell aggressive lymphoma , confirm MSKCC pathologist : Diffuse Large , Immunoblastic , Mantle cell , Anaplastic Large Cell , De novo transformation follicular lymphoma , classical Hodgkin 's lymphoma CD20 antigen positive . Tumors must stain positive CD20 . Primary refractory disease proven biopsy fine needle aspiration ( cytology ) involve site Relapsed diffuse large , immunoblastic , anaplastic , de novo transformation follicular lymphoma , classical Hodgkin 's lymphoma CD20 antigen positive proven biopsy fine needle aspiration ( cytology ) involve field site least two three follow risk factor : LDH &gt; upper limit normal , KPS &lt; 80 % , Stage III IV disease . All mantle cell lymphoma patient first relapse Failure doxorubicin mitoxantrone contain frontline therapy Bidimensionally measurable disease . Cardiac ejection fraction great 50 % , measure since last chemotherapy . Serum creatinine &lt; 1.5 mg/dl ; creatinine &gt; 1.5 mg/dl measure 12 24hour creatinine clearance must &gt; 60 ml/minute . ANC &gt; 1000/µl Platelets &gt; 50,000/µl Total bilirubin &lt; 2.0 mg/dl absence history Gilbert 's disease . Females childbearing age must acceptable form birth control . Age 18 72 HIV I II negative . Patients guardian must capable provide informed consent . Any lymphoma subtype describe among inclusion criterion . All patient relapse diffuse large , immunoblastic , anaplastic , de novo transformation follicular lymphoma , classical Hodgkin 's lymphoma CD20 antigen positive disease &lt; 2 follow risk factor : LDH &gt; upper limit normal , KPS &lt; 80 % , Stage III IV disease . History secondline chemotherapy Presence CNS involvement . Prior treatment carboplatin , cisplatin , ifosfamide , etoposide Hepatitis B surface antigen positive . Known pregnancy breastfeed . Medical illness unrelated NHL , opinion attend physician and/or principal investigator preclude administer chemotherapy safely . History malignancy diseasefree interval &lt; 5 year , exclude curatively treat cutaneous basal cell squamous cell carcinoma carcinoma insitu cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>ASCT</keyword>
	<keyword>B-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Second line therapy</keyword>
	<keyword>ICE</keyword>
	<keyword>Stem cell transplant</keyword>
</DOC>